Learn about MSK’s Healthy Living, a lifestyle program for people with breast cancer, where diet, nutrition, exercise and integrative medicine come together to improve quality of life.

Obtenga información sobre cómo los expertos en cáncer pulmonar de MSK usan quimioterapia, inmunoterapia y otras terapias sistémicas para tratar el cáncer pulmonar de células pequeñas y de células no ...

When you learn you have lung cancer, you’ll probably have many questions. Talking about treatment options with your doctors can help you feel confident when making decisions about your care ...

Memorial Sloan Kettering Cancer Center (MSK) and Curadev Pharma, Inc., a biotechnology company developing novel immuno-oncology therapeutics, are expanding their collaboration through the MSK ...

The Hite laboratory studies the mechanisms of ion and metabolite transport and the maintenance of genomic integrity.

Full Title A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs. Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) /Lymphoplasmacytic Lymphoma ...

I am currently a PhD student working in the labs of Dr. Daniel Heller and Dr. Raphael Lis. Here I am using organoid models to further our understanding of heterogeneity across brain vasculature, and ...

Discover the joys of crafting your very own DIY terrarium and transform your space into a green oasis! Whether this is your first time or you are a crafty botanical enthusiasts, this virtual workshop ...

New MSK research finds improving intestinal metabolism may help treat chronic inflammation and prevent cancer; shows how breast cancer resistance is linked to APOBEC3 enzymes; investigates ...

An MSK clinical trial found that participating in integrative therapy classes online could benefit cancer patients in active treatment, not only by reducing fatigue, anxiety, and depression but also ...

Memorial Sloan Kettering Cancer Center (MSK) announced today that Jeffrey A. Drebin, MD, PhD, has been named Chief Physician Executive. A renowned surgeon-scientist, Dr. Drebin previously served as ...

Event-free survival (EFS) was 27% higher for patients with locally advanced head and neck squamous cell cancer (HNSCC) who received standard-of-care with neoadjuvant and adjuvant pembrolizumab ...